REAlease CD158b (KIR2DL2/DL3)-APC, human，130-123-074，美天旎

Clone REAL473 is an antibody fragment derived from the full CD158b (KIR2DL2/DL3) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL473 recognizes the human CD158b1 (KIR2DL2), CD158b2 (KIR2DL3), and CD158j (KIR2DS2) antigens, members of the killer immunoglobulin-like receptor (KIR) family expressed on natural killer (NK) cells and subsets of T cells.

KIRs contribute to the regulation of NK cell–mediated cytotoxicity and possess high allelic polymorphism with either 2 or 3 Ig-like extracellular domains. According to the length of their cytoplasmic tail, KIRs can be further subdivided in inhibitory KIRs (KIR2DL or KIR3DL) and activating KIRs (KIR2DS or KIR3DS). CD158b provides an inhibitory signal on NK cell lytic activity upon interaction with HLA C (e.g. alleles HLA-Cw1, HLA-Cw3, HLA-Cw7) in an antigen-independent manner.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

KIR2DL2, KIR2DL3, KIR2DS2

Technical specifications